AstraZeneca live at WCLC, ASH and SABCS


We are excited to end 2016 with a strong scientific communications presence at three major congresses. A total of 48 abstracts, including 16 oral presentations, have been accepted across:


ASH: the 58th American Society of Hematology Annual Meeting

WCLC: the 17th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer

SABCS: the San Antonio Breast Cancer Symposium

3-6 December 2016, San Diego, USA


4-7 December 2016, Vienna, Austria


5-10 December 2016, San Antonio, USA.





American Society of Hematology Annual Meeting (ASH)

Our presence at ASH 2016 will focus on new data in patients with difficult-to-treat chronic lymphocytic leukaemia. This comes less than a year after we announced a majority investment in Acerta Pharma, which is becoming our haematology Centre of Excellence.




World Conference on Lung Cancer (WCLC)


At WCLC 2016, we will shine the spotlight on our lung portfolio, with confirmatory results in patients with advanced non-small cell lung cancer (NSCLC), data on novel mutation testing methods for patients with NSCLC and latest research into patients with NSCLC and brain metastases.






San Antonio Breast Cancer Symposium (SABCS)

At SABCS, our data presentation data will build on previous findings in women with advanced hormone-receptor positive breast cancer, including an analysis in women with and without metastases that have spread to the liver and/or lung, so-called visceral disease.




Page Atlas ID: 1024017.011
Date of next review: December 2017